Wednesday, December 08, 2010

ACTC Shares Jump on Excitement

ACTC has had a very nice run over the last week.  The share price has increased from around five cents to fifteen cents. Shareholders of ACTC have to be doing the stock dance, but will it continue? I have seen this in the past, the buying drys up, and the share price falls.  I wonder just how much ACTC stock will appreciate?  Perhaps this will be one of those penny stock which runs from pennies to over a dollar.  Please refer to my previous posts about ACTC.

Risky investments, and anyone considering investment in them should do so knowing their entire investment could be lost.  Only make investments with the advice of a registered investments advisor.

As a result of the reverse stock split, every 100 shares of the Company’s pre-reverse stock split common stock were combined and reclassified into one share of the Company’s common stock. Beginning with the opening of trading on August 28, 2014, the Company’s common stock will trade on the OTC Markets Group on a reverse stock split adjusted basis.  

Now trading under the symbol OCAT.

Thursday, December 02, 2010


"Blue Sphere Corp. Submits Product Identification Note for One of its Projects in Ghana
Dec. 2, 2010 (Filing Services Canada) -- Blue Sphere Corporation (BLSP - OTCBB),(the 'Company' or 'Blue Sphere'), a company in the Cleantech sector as an Emission Reduction project integrator, is pleased to announce that it has submitted the Project Identification Note ('PIN') to the Ghanaian government for preliminary approval of its landfill gas mitigation clean development mechanism ('CDM') project in Accra.

Mar 25, 2015, Blue Sphere Corp. (the "Company" or "Blue Sphere"), a clean energy company that develops, manages and owns waste-to-energy projects, announced that on Monday March 23, 2015, it broke ground on both its first waste-to-energy project and new US headquarters in Charlotte, NC.

OTCBB Pennystock, GTHP Stock News

"FDA Accepts Guided Therapeutics' Non-Invasive Cervical Cancer Scanner PMA Application for Review

Dec. 2, 2010 (Business Wire) -- Guided Therapeutics, Inc. (OTCBB & OTCQB: GTHP stock news) announced that it was notified by the U.S. Food and Drug Administration (FDA) that the company’s premarket approval application (PMA) for the LightTouch™ Cervical Scanner, for patients at risk for cervical cancer, is “suitable for filing.”

GTHP Message Board News, Charts, and More on GTHP

OTCBB Stock News and Information About the OTCBB trading platform, and listing information.

Penny Stocks Trading help Learn about how penny stocks generally trade, and how to avoid the big mistake.

Pink Sheets Listing, and Trading Information. Learn about the pink sheet stocks, and how they can help your company move forward.

Twitter, and Facebook strategies for Investor Relations. Sick of holding issued stock you don't want?

The same old crap in investor relations is not working! We know why, and we can help deliver outstanding results using social media. Twitter and Facebook are only two of the many outlets of socialmedia being used to deploy investor relations successfully. We know how to use social media to deliver results in investor relations for penny stocks, OTCBB, and pink sheets! Give us a call if your company has great products and poor investor relations! Visit GroupVenture, DONT'T fall for the same old crap, promise the world, and deliver nothing programs. We're not promising the world, but we will deliver!

Penny Stocks, DIGA Wins Case

In a unanimous jury verdict DIGA win case brought by former CEO Michael Krawitz.  The jury declined to make an award in the case.

“We are pleased to be able to put this baseless lawsuit behind us,” commented Digital Angel CEO Joseph J. Grillo. “This case, along with other legacy issues inherited from prior management, has been an enormous drain on current management’s time and resources and we are gratified that the jury found the lawsuit’s claims to be without merit by granting the Company an unqualified victory in the matter. This will be one less distraction for us as we continue to focus on improving the operational and financial performance of the Company.”

Always consult a registered investment advisor before making an investment. Penny stocks are very risky and can result in entire loss of investment.

Wednesday, November 24, 2010

IRE I Almost Bought, Buy, Sell, Hold?

I thought I was going to get to take a risk on IRE  at the close yesterday, for some reason I decided against it.  However, I immediately regretted not buying it when news surfaced that pushed shares of IRE back to $2. This mornings opening looks to put my regret in check, in a sudden reverse shares of IRE are now down further than before yesterdays close.
News that the Irish government will increase its holdings in IRE and likely dilute an already battered stock. Is IRE oversold at these levels? Assuming that IRE, and Europe altogether will emerge from this crisis, yes I think there could be some profit to be made in IRE stock.  However, I am not a registered financial adviser, so my opinion only counts for my portfolio.
Citigroup received significant cash, and debt relief from the US Government and the stock has performed fairly well from its lows.  However, FRE, and FNM have not performed as well! I am not yet willing to buy IRE, but I am watching closely!

Always consult with a registered financial adviser before making any investment decision. Penny stocks investing is risky and can result in entire loss of investment.

Monday, November 22, 2010

ACTC Massive Volume

Does massive volume mean a stock is good, I think not.  Things that make a stock good are the same that make a company good. Great products and the potential for profit are key to making a good company and a good stock. Buying a penny stock just because it's relatively cheap, and a dollar buys many shares is not good reason for purchasing a common stock. It looks like ACTC in recent press releases and an 8k announced clearance for the first clinical trial of its' products. There is ton of speculation about the potential of embryonic stem cells and their potential to cure illnesses. The speculation is represents promise of future demand for the products if they work.  However, there is no promise ACTC will ever produce a product which will be accepted by the FDA,or that the product will work.
Investors have made huge profits betting on early stage drug companies. Early investors in PFE, MRK, and DNDN have reaped tremendous profits.  However, there are many more investors who lost most or all of their investments in similar companies who's products ultimately failed to work.
Buying into early stage drug stocks can be very risky and entire investments could be lost. There is not guarantee that ACTC will ever produce product demanded in the market. Always consult a registered investment adviser before investing. Investing in penny stocks is very risky and can result in entire loss of investment.

Join the ACTC Stock Investors Social Network

If you are seeking the ultimate investor relations solution, visit to find out about it. has pionered many of the new investor relations strategies in the market.

IRE, Bank of Ireland Bailout, Buy, Sell, or Hold?

As the market closed on Friday, I decided to avoid purchasing shares of IRE stock. I liked the idea of a looming bailout, and a potential bounce. However, as the bailout is unfolding shares of IRE are down significantly in pre-market trading. The market does not feel bailouts are going to be enough to bring world economies out of their current funk. While a bailout will prevent a present failure, it does not guarantee there will be a recovery and eventual return to a healthy market. I am glad I held off on a purchase of IRE shares, maybe I will pick some up on the oversold side.

Always consult a registered investment adviser before making any investment decision. Penny stocks are very risky and investing in them can result in entire loss of investment. PennyMarkets contributors are not registered investment advisers.

If you are seeking pink sheet, OTCBB, or penny stock investor relations please consider as your solution. Investor relations fulfillment services have changed significantly over the last few years and we have helped lead the change.

Friday, November 19, 2010

IRE Bank of Ireland, Buy, Sell, Hold?

A lot of investors are wondering about what to do with the Bank of Ireland, I'm wondering too.  If they get a good deal over the weekend, the stock could push higher, much higher. However, if the deal is unfavorable, the stock could go lower. I opted to stay away!

Always contact a registered investment adviser before making any investment decision! Penny stocks are risky, and can result in loss of investment. Only highly skilled traders, with the consult of registered investment advisers should make any pennystock investment.

Friday, November 12, 2010

Breaking Down NEOP Third Quarter 2010

 Revenues Up 6% and Gross Profit Increases 10% Year-to-date

 Neoprobe Corporation (OTCBB: NEOP), developer of diversified innovative oncology surgical and diagnostic products, announced today its consolidated 2010 results for the third quarter and for the 9 months period ending September 30, 2010.
Revenues for the 2010 third quarter were $2.3 million compared to $2.6 million for the third quarter of 2009, an 11% decrease as revenues in the third quarter of 2009 were unseasonably high and included initial stocking orders for new products.
They are saying that demand was especially high, and not to expect that every quarter.
Gross profit remained steady at $1.7 million for the third quarter of 2010 compared to the third quarter of 2009 despite the decline in revenues. Third quarter 2010 operating expenses were $3.9 million compared to $2.0 million for the third quarter of 2009, primarily as a result of the Company’s continued investment in its Lymphoseek® drug initiative. Loss from operations for the third quarter of 2010 was $2.2 million compared to $324,000 for the third quarter of 2009.
Loss and operating expenses have increased significantly, I would like to review payroll.
2010's third quarter, Neoprobe reported a net loss attributable to common stockholders of $2.4 million, or $0.03 per share, compared to a net loss attributable to common stockholders of $25.1 million, or $0.34 per share, for the third quarter of 2009. As discussed more fully below, the net losses attributable to common stockholders for the third quarter of 2009 include significant non-cash losses aggregating $22.6 million (Alarming.) These non-cash losses were due to the extinguishment accounting treatment related to the modification of certain terms of the Company’s convertible debt, preferred stock and related warrants in July 2009 as well as mark-to-market adjustments related to derivative accounting treatment required for certain financial instruments on the Company’s balance sheet, most of which were modified in the July 2009 transaction.
Present revenues for the 9 month period ended September 30, 2010 were $7.5 million compared to $7.1 million for the same period in 2009, a 6% increase. Gross profit was $5.2 million for the nine-month period ended September 30, 2010 compared to $4.7 million for the same period in 2009, a 10% increase. Operating expenses for the nine-month period ended September 30, 2010 were $10.1 million compared to $6.1 million for the same period of 2009. Neoprobe’s loss from operations for the nine-month period ended September 30, 2010 was $4.9 million compared to $1.4 million for the same period in 2009.
Increased revenue, but even greater increase in loss.
For the nine-month period ended September 30, 2010, Neoprobe reported a net loss attributable to common stockholders of $56.1 million, or $0.70 per share, compared to a net loss attributable to common stockholders of $39.5 million, or $0.56 per share, for the same period in 2009. As discussed more fully below, the net loss attributable to common stockholders for the first nine months of 2010 and 2009 included significant non-cash losses and deemed dividends aggregating $50.4 million and $34.8 million, respectively. In 2010, these non-cash charges were primarily due to the extinguishment accounting related to the June 2010 exchange of the Company’s previous convertible debt and preferred stock for a new series of preferred stock and to mark-to-market adjustments related to derivative accounting treatment required for certain financial instruments on the Company’s balance sheet. In 2009, these non-cash charges included the extinguishment accounting related to the modification of certain terms of the Company’s convertible debt, preferred stock and related warrants and the mark-to-market adjustments related to derivative accounting treatment required for certain financial instruments on the Company’s balance sheet at that time.
Brent Larson, Neoprobe’s Senior Vice President and CFO, said, “Revenue increased on a year-to-date basis despite being lower for the quarter than in the prior year. Third quarter 2009 revenues were unseasonably high and included some initial stock orders on new products. More importantly perhaps than the year-to-date revenue increase, our gross margins have continued to improve. For the third quarter of 2010, gross margin rose to 73% of revenue compared to 64% for the third quarter of 2009 due to the receipt of grant funds, favorable pricing and lower material costs. This positive margin movement in the third quarter contributed to an overall increase in our year-to-date gross margin of 69% for the nine months ended September 30, 2010 compared to 67% for the same period in the prior year. We are pleased with our ongoing efforts to effectively manage our device business coupled with the non-dilutive contributions that our grant application efforts are starting to provide.”
I hope the business module does not include grant money, the Government is broke.
David Bupp, Neoprobe’s President and CEO, said, “Our operating expenses during the first nine months of 2010 increased as a direct result of our progress in clinical, manufacturing and regulatory activities related to our Lymphoseek drug initiative. We put in a great deal of effort in 2010 to be in a position to file our new drug application (NDA) for Lymphoseek. That effort has served us well as we now expect to file the NDA shortly following the completion of patient enrollment in our ongoing NEO3-09 Phase 3 clinical trial in patients with breast cancer or melanoma.”
“We are pleased with the progress we’ve made with the clinical and regulatory pathway for Lymphoseek,” Bupp continued. “We are also continuing our efforts to move our biologic development activities ahead to support a second advanced-stage clinical program with RIGScan CR. We have successfully completed the re-characterization of the RIGScan CR biologic agent and are now preparing an investigational new drug (IND) amendment and a Phase 3 clinical protocol to support the ongoing clinical development program.”
The following are some of the milestones achieved by Neoprobe so far in 2010:
  • Completion of a successful meeting with FDA to review the Phase 3 (NEO3-05) clinical study results and development plan discussion to support a NDA submission for Lymphoseek as a lymphatic-tissue tracing agent;
  • Completion of successful pre-NDA dialogue with FDA on Lymphoseek pre-clinical data;
  • Completion of successful pre-NDA dialogue with FDA on Lymphoseek chemistry, manufacturing and control data;
  • Election of two new directors to Neoprobe’s Board, bringing significant drug industry and corporate development expertise to the Company’s leadership;
  • Completion of exchange transactions that converted all of the Company’s outstanding debt to equity;
  • Initiation of a third Phase 3 Lymphoseek clinical study in patients with breast cancer or melanoma to support the filing of the NDA with the potential to expand Lymphoseek’s product labeling;
  • Achieved revenue and gross margin increases of 6% and 10%, respectively, for the first nine months of 2010 over 2009;
  • Completion of preliminary RIGS® development activities including transfer of biologic license application to CDER and preparation of an IND for the biologic product;
  • Received notice of grant awards totaling over $1.2 million to support Lymphoseek development through non-dilutive funding;
  • Completion of a pre-NDA meeting for Lymphoseek clarifying the regulatory pathway for Lymphoseek approval;
  • Filed a complete response to the open biologic license application (BLA) for RIGScan CR;
  • Filing of a shelf registration on Form S-3 to allow the Company to raise capital as necessary through the sale of up to $20 million in a primary offering of securities to provide us with additional financial planning flexibility and to support the diversification of our share ownership to new institutions; and
  • Completion of a $6 million equity financing for working capital purposes and to support ongoing development efforts.
“In summary, our gamma detection device business continues to demonstrate positive performance,” Bupp continued. “We had completed preparation of the Lymphoseek NDA last month without the clinical data from NEO3-09. Since FDA would like the data filed with the primary NDA, we may have the opportunity to launch the product with the enhanced labeling. We are encouraged with the biologic characterization information for the RIGS technology obtained to date. Lastly, we believe our recently completed financing should buoy investor confidence regarding our ability to both reach our near-term milestones such as the commercialization of Lymphoseek and to take critical steps toward our longer term product development goals regarding RIGScan.”
Under the applicable accounting rules for complex financial instruments, embedded features in certain of the Company’s notes and preferred stock and the warrants to purchase common stock that have been issued from time to time have been considered derivative liabilities because these instruments contained language that provided for the resetting of the instruments’ exercise/conversion prices in the event that the Company issued common stock at prices below the exercise/conversion prices of the respective instruments. Treatment of these instruments as derivative liabilities resulted in them being required to be reflected on the Company’s balance sheet at their fair values (i.e., marked to market) based on certain assumptions, including the trading price of the Company’s common stock. As the share price of the Company’s common stock increased over a given period, significant mark-to-market adjustments were recorded as non-cash expenses in the Company’s statements of operations. Neoprobe’s management believes that the inclusion of such mark-to-market adjustments in the Company’s financial results does not appropriately communicate the results of the Company’s operating performance and development activities to our investors. As a result, Neoprobe’s management believes the ability of investors to analyze Neoprobe’s business trends and to understand Neoprobe’s performance may be better served from reviewing certain operational measures such as revenues, development expenses and income (loss) from operations.
On July 24, 2009, Neoprobe agreed with the holder of a majority of the instruments with derivative characteristics, Platinum-Montaur Life Sciences, LLC (Montaur), to eliminate the price reset features that had substantially caused the derivative treatment of the instruments thereby permitting the Company to effectively extinguish the majority of its derivative liabilities. During the third quarter of 2009, the Company recorded $6.3 million in mark-to-market adjustments related to movement in the price of the Company’s common stock. This contributed to a net total mark-to-market adjustment of $18.5 million being recorded for the first three quarters of 2009. As a result of the extinguishment treatment associated with the elimination of the price reset features, the Company recorded $16.2 million in non-cash loss on the extinguishment during the third quarter of 2009 and reclassified approximately $27 million in derivative liabilities to additional paid-in capital.
During June 2010, Neoprobe’s primary investor, Montaur, agreed to exchange all $10 million of its outstanding 10% senior secured convertible notes and all $3 million of its perpetual convertible preferred stock for a single new series of preferred stock convertible into 32.7 million common shares. Under the terms of the transaction, Montaur’s $7 million Series A Convertible Secured Note (originally convertible into 17.1 million common shares), $3 million Series B Convertible Note (originally convertible into 8.3 million common shares) and Series A Convertible Preferred Stock (originally convertible into 6.0 million common shares) were exchanged for Series B Convertible Preferred Stock (the Series B Preferred, convertible into a total of 32.7 million shares). As part of the consideration for the conversion, Neoprobe “prepaid” interest and dividends due through the original note maturity in December 2011 by agreeing to issue Series B Preferred which is convertible into 1.3 million shares of common stock on the conversion of the new Series B Preferred. The Series B Preferred is convertible at the option of Montaur but carries no dividend and has no liquidation preference over the common stock. The Series A Convertible Preferred Stock was convertible at the option of Montaur and paid an 8% dividend until converted. Under the applicable accounting rules for financial instruments, the exchange transactions were accounted for as extinguishments of the old instruments which resulted in the Company recording non-cash losses on extinguishment of all of the Company’s secured debt of $41.7 million related to debt instruments and a deemed dividend of $8.0 million related to the retirement of the Series A Preferred Stock. These charges accounted for the vast majority of the losses attributable to common stockholders for the nine-month period ended September 30, 2010, respectively. Excluding these non-cash losses, we would have reported losses attributable to common stockholders $0.08 per share for the nine-month period ended September 30, 2010.
Neoprobe’s President and CEO, David Bupp, Senior Vice President, Pharmaceutical Research and Clinical Development, Dr. Frederick Cope, and Senior Vice President and CFO, Brent Larson, will provide a business update and discuss the third quarter of 2010 during a conference call with the investment community scheduled for later this afternoon at 4:30 PM ET. The conference call can be accessed as follows:
Conference Call Information
Date:   November 10, 2010     Available until:   November 24, 2010
Time: 4:30 PM ET
Toll-free (U.S.) Dial in # :
International Dial in # :
Toll-free (U.S.) Dial in # :
Replay Passcodes:
International Dial in # :
Account #:
          Conference ID #:  
About Neoprobe
Neoprobe is a biomedical company focused on enhancing patient care and improving patient outcome by meeting the critical intraoperative diagnostic information needs of physicians and therapeutic treatment needs of patients. Neoprobe currently markets the neoprobe® GDS line of gamma detection systems that are widely used by cancer surgeons. In addition, Neoprobe holds significant interests in the development of related biomedical systems and radiopharmaceutical agents including Lymphoseek® and RIGScan® CR. Neoprobe’s subsidiary, Cira Biosciences, Inc., is also advancing a patient-specific cellular therapy technology platform called ACT. Neoprobe’s strategy is to deliver superior growth and shareholder return by maximizing its strong position in gamma detection technologies and diversifying into new, synergistic biomedical markets through continued investment and selective acquisitions.

Thursday, November 11, 2010

Oil and Gas Penny Stocks List

Upstart IPRC is looking to develop shallow oil and gas developing wells in Texas eastern shelf region. The company believes a potential exists to drill 5 wells producing in excess of 35,000 barrels of oil and 60,000, mcf of gas per well.

About Imperial Resources, Inc. IPRC

Imperial Resources, Inc., through its wholly owned subsidiary, Imperial Oil & Gas, Inc. has a highly focused, risk-averse strategy of building a substantial portfolio of oil and gas assets through its access to niche, low risk oil and gas opportunities in the onshore U.S. Imperial aims to exploit projects which can deliver cash flows normally associated with higher risk projects but without exposure to high risk failure rates.

SKPI has had a nice return over the last few months.  The price of crude oil hovers above $80 per barrel and has helped boost the share price of many oil and gas penny stocks. I hope the chart for SKPI continues to look good.

About the Republic of Albania SKPI

Albania has a population of 3.5 million people and is located 50 km east of Italy, across the Adriatic Sea in Southeast Europe. Albania is a member of NATO, and has applied to join the European Union. Albania is a proven hydrocarbon producing region with earliest known bitumen production dating back to the Roman Empire. Modern exploration began in the early 1900’s. The Patmos – Marinza and Kucova heavy oilfields are among the largest oilfields in Europe. To date there have been ten significant field discoveries that have produced more than 150 million barrels. 

Has anyone been watching SROE? With increasing crude oil prices small companies like SROE could see significant share price appreciation. I am going to start a list of oil and gas penny stocks to watch.  I will keep them posted in this blog post, and add their tickers to the labels section.

About Saratoga Resources SROE, Now SARA
Saratoga Resources, Inc. is an independent exploration and production company with offices in Houston, Texas and Covington, Louisiana. Principal holdings cover 33,625 gross (32,527 net) acres, mostly held-by-production, located in the transitional coastline and protected in-bay environment on parish and state leases of south Louisiana. Saratoga's stock currently trades on the OTC Bulletin Board under the symbol "SROE".]
The company went through bankruptcy, and left shareholders intact.  They are now listed under the ticker SARA.

Tuesday, November 09, 2010

ABK Finished, Files for Chapter 11

I think we all knew what was coming with Ambac.  The company has recently filed for chapter 11, and claims the IRS is ruining their bankruptcy by claiming $700 million in tax refunds. If the IRS is successful, Ambac claims they will not emerge from bankruptcy. Shares of ABK  have traded as high $3 this year, and $1 more recently. However, ABK is a very risky penny stock and only should have been traded with the consult of a registered investment advisor.
I made a 270% profit trading ABK earlier in the year, purely a momentum trade. The stock has just been to volatile for my trading preference. I commented on the stock more recently and determined that only extreme risk takers should be considering ABK, and only with the advice of a registered investment adviser.

Pennystocks are risky, and any investing should be done with the advice of a registered investments advisor!

Monday, November 08, 2010

NEOP Holds Ground

Shares of Neoprobe continue to hold their ground.  After years of anguish shareholders of Neoprobe are enjoying significant appreciation in their holdings of NEOP.

Neoprobe Corporation (OTCBB:NEOP) is a biomedical company focused on enhancing patient care and improving patient outcome by meeting the critical intraoperative diagnostic information needs of physicians and therapeutic treatment needs of patients. Neoprobe currently markets the neoprobe® GDS line of gamma detection systems that are widely used by cancer surgeons. In addition, Neoprobe holds significant interests in the development of related biomedical systems and radiopharmaceutical agents including Lymphoseek® and RIGScan. Neoprobe’s subsidiary, Cira Biosciences, Inc., is also advancing a patient-specific cellular therapy technology platform called ACT. Neoprobe’s strategy is to deliver superior growth and shareholder return by maximizing its strong position in gamma detection technologies and diversifying into new, synergistic biomedical markets through continued investment and selective acquisitions.

Always consult a registered investment adviser before making investment decisions. Penny stocks are extremely risky and can result in entire loss of investment.

Monday, November 01, 2010

ABK Ambac Slammed On Missed Paymet

Shares of ABK were down %40 in early trading as news crossed the wires that company had missed an interest payment. The company also disclaimed that they might file bankruptcy before the end of the year.

Ambac Slammed on bankruptcy warning

ABK said in a regulatory filing that its board decided not to make an interest payment that was due Monday on 7.50% debentures that mature May 1, 2023.

Ambac had $1.62 billion in debt at the end of June. It’s next interest payment is due on Nov. 15.
The company also said it hasn’t been able to raise new capital as an alternative to seeking bankruptcy protection from creditors.

Ambac has been working with an ad-hoc committee of senior debt holders to try to restructure its debt through a pre-packaged bankruptcy filing. If it can’t agree to such a plan, Ambac said it will file for Chapter 11 bankruptcy protection from creditors before the end of 2010.

As we can see pennystocks are unstable, and losses can happen.  Always consult an investment adviser before making an investment.

Older ABK,Ambac Post

GSLO GoSolarUSA Using Yahoo Ad System

Today I noticed the ticker symbol for GSLO on the Yahoo ad system. This is an investor awarness format I tested in 2004 with a great deal of success.  The problem I have with it is that advertisers are placing the ticker symbols of the companies in  advertisements. This practice of placing the ticker symbol in the advertisement is a benefit to the advertiser because the potential for stock purchase exists without an actual clickthrough. I have also seen this activity on Facebook, and Google/adwords. I do not know if the practice is legal. Many penny stock promoters have began to use this practice. Only time will tell if this investor relations practice will continue to be allowed  by FINRA. I do not know anything about GoSolarUSA or their business model. I have posted their business profile below.

About GoSolarUSA, Inc.
GoSolarUSA primarily identifies and develops new solar energy technologies in the United States. We believe this not only creates high-quality jobs in America, but it ensures the quality and availability of our products. GSLO is endeavoring to advance clean American solar technology to compete in an energy industry that includes stalwarts such as First Solar . GoSolarUSA is a US registered and reporting OTCQB market tiercompany.


GoSolarUSA, Inc.
Tyson Rohde, 504-599-5979
President and CEO

Thursday, October 28, 2010

Is Cloud Computing The Answer?

OTCBB:VCLD, Verecloud hopes so. However, I have my doubts! I grabbed this profile of Verecloud from their recent press release. I think we will have to see further development before widespread acceptance of the technology.

About Verecloud 

Based in Englewood, Colorado, Verecloud enables communications service providers (CSPs) to capture market share in the expanding and lucrative cloud computing market. Verecloud's cloud services broker platform, Nimbus Xchange, addresses the CSPs' need to integrate their cloud services business with existing back-office systems which enable CSPs to drive new revenue opportunities. By collaborating with Verecloud, CSPs are positioned to capture a significant percentage of this exciting market by playing a key role in the cloud services brokerage opportunity. Learn more about Verecloud at:

Always consult a registered investment adviser before making any investment decision. PennyMarkets and its contributors are not registered investment advisers.  Penny stock investments can result in entire loss of investment.

Tuesday, October 19, 2010

Turbulent ABK Shares Pass $1 Again, Up 24%

The last few days of trading for ABK shareholders have been turbulent.  The stock has risen above $1, and has fallen back below. Shareholders must be expecting another bounce, but will it happen? There were no clear causes for the 24% increase in share price.  Penny stocks can be very volatile, as we can see in the trading range for ABK. The recent volatility in share price could be due to short covering, maybe! I made a small fortune the last time ABK ran up, I hope others get the same opportunity!

Always consult a registered investments adviser prior to making any investment, especially when considering penny stock investments! Investing in penny stocks can result in total loss investment.

Sunday, October 17, 2010

ZAGG No Longer a Penny Stock, But!

I realize ZAGG is no-longer a penny stock, but the stock represents a real opportunity for gains, IMHO! I wrote about the company when Verizon (VZ) started selling the MOTOROLA (MOT) DROID . At the time the share price was near where it is today, but today there is IMHO much more potential for gain. My guess is that we will continue to see increased demand for ZAGG products which are used to protect electronics devices like the Apple (AAPL) iPad, and other devices. The company recently released news that their numbers are much better than expected!

"Zagg also lifted its full-year forecast. The company now expects revenue for 2010 will be up 70 percent over 2009 levels, suggesting $65 million. That's up from a previous forecast for a 30 percent increase."

Always consult a registered investment adviser prior to making any investment.

GETA Changes Symbol to GNTA

Genta Incorporated (OTCBB: GETA.OB) has announced the Financial Industry Regulatory Authority (FINRA) has allowed the Company’s request to change their trading symbol to GNTA.OB, the change will replacethe current trading symbol GNTA.OB. The ticker change will effect the opening of trading on Monday October 18, 2010.

Penny stocks represent a great deal of risk, always consult a registered investment adviser before investing.

Tuesday, October 12, 2010

Hot Off The Press EVSI Selected By General Motors

I thought this was pretty good news, EVSI had no volume today. I expect to see some activity in the market for EVSI tomorrow. The news hit the wires well after the market closed today.

General Motors Selects Envision Solar's EnvisionTrak(TM) Solar Trees(R), CleanCharge(TM) Electric Vehicle Charging Infrastructure

Envision Solar International, Inc., (EVSI ) , a leading sustainable infrastructure designer and developer, announced today that the company has been selected by General Motors, LLC to install its CleanCharge(TM) solar powered electric-vehicle (EV) charging stations integrated into EnvisionTrak(TM) tracking Solar Trees(R) at a number of prominent locations.

"We are pleased to have been selected by General Motors for these strategic installations that will enable Chevy Volts to leverage clean solar power to recharge their batteries without relying on carbon fuel generated electricity," said Bob Noble, CEO of Envision Solar. "We applaud GM's commitment to clean energy as well as green job creation through this initiative."

The Chevy Volt extended-range electric car is expected to hit showrooms in November 2010 and will be rolled out initially in California, Michigan, Washington, D.C., Texas and New York. New Jersey and Connecticut will join in mid-2011.

"GM is committed to reducing carbon emissions and reliance on petroleum," said Tom Stephens, GM vice chairman, global product operations. "We chose Envision Solar because its clean charging infrastructure allows us to maximize the environmental benefits of our electric vehicles through the use of clean renewable energy and further demonstrates our commitment to the proliferation of sustainable EV charging infrastructure."

Envision Solar's Solar Tree with EnvisionTrak(TM) is a highly engineered parking lot solar array that is 20 to 25 percent more productive than conventional fixed solar arrays, due to the incorporation of dual access tracking which enables the canopy to follow the sun throughout the day. "We have designed this technology with an architectural focus that enhances the overall aesthetic of corporate and commercial campuses," Noble added. "The addition of our CleanCharge system makes this a truly comprehensive design and technology package, offering a value-added investment for businesses anticipating the dramatic growth in the electric vehicle market over the next decade."

Pike Research forecasts that the market for plug-in hybrid and battery electric passenger cars and light duty trucks will grow at a compound annual growth rate (CAGR) of 106 percent between 2010 and 2015, resulting in sales of more than 3.24 million vehicles during that period.

About Envision Solar International, Inc.

Envision Solar,, is a leading solar planner, architect and inventor designing and deploying clean energy systems globally. The solar master planning firm provides strategic long-term solutions including comprehensive sustainability planning and optimizing designs for solar array structures. The company is a leader in the invention and construction of solar structures that address unused millions of acres of parking spaces. Its innovative systems include products for commercial, residential, and institutions, such as the Solar Tree(R), Solar Grove(R), Solar Row(TM), LifePort(R), LifePod(TM), LifeVillage(TM) and others. Envision Solar is listed on the OTC Bulletin Board under the symbol [OTCBB: EVSI]. For more information on the company, contact 1-866-746-0514.

If you are interested in EVSI and this news, visit this site and chat it up!

Always consult a registered investments adviser prior to making an investment, especially in penny stocks!

WYNX Three Month Chart Rocks, BUT!

For the three months ended September 30, 2010, CUI received new sales orders in the amount of $12,011,947. These numbers represent a 67% year-over-year increase in new orders, up from $7,204,228 in the third quarter 2009.

Significantly, the year-to-date numbers also reflect a dramatic increase to $32,176,698 in sales orders through September 30, 2010 from $19,237,430 in 2009. This represents a growth rate of more than 67% or up $12,939,267.


Okay, that's great, but lets talk about completed sales. Orders are great, but the product has to be manufactured and shipped to the the customer and the customer has to make payment. I appreciate the market CUI is operating in, but I am cautious of their current debt to cash ratio. Additionally, I am encouraged with Wells Fargo Capital extending an $8 million credit facility. Again, sales orders are great, but they have to be completed!

About Waytronx, Inc.

Waytronx, Inc. has pioneered and is developing innovative thermal management solutions capable of revolutionizing the semiconductor, solar and electronic packaging industries, among others, utilizing its patented WayCool(TM)/WayFast(TM) hybrid mesh architecture. In addition, through its acquisition of CUI in May 2008, Waytronx has developed the infrastructure, expertise, and platform necessary to acquire, develop, and commercialize new technologies. For its part, CUI is a solutions provider of electromechanical components and industrial controls for OEM manufacturing. Since its inception in 1989, CUI has been delivering quality products, extensive application solutions, and superior personal service. CUI's solid customer commitment and honest corporate message are a hallmark in the industry.

Always consult a registered investment adviser prior to making any investment. Stocks  general are risky, however pennystock investments are especially risky.

Are you interested in WYNX? Chatit up with WYNX shareholders

Tuesday, October 05, 2010

BFRE BlueFire Renewables Slammed %18 on Good News?

  • So BFRE is spending $296 million! What is going to drive demand for the product? 
  • Their are alternative fuel companies which are not operating at full capacity now! Does BFRE offer a suitable product at a lower cost of production than their competitors? 
  • I'm just trying to understand how this is a good thing for BlueFire Renewables shareholders.

BlueFire Renewables, Inc. (OTCBB: BFRE),  focused on changing the world's transportation fuel paradigm through the production of renewable fuels from non-food cellulosic wastes, announced that it has finalized and signed an Engineering, Procurement and Construction (EPC) contract for its planned cellulosic ethanol facility in Fulton, MS.  The facility will be engineered and built by Wanzek Construction, Inc., a wholly owned subsidiary of MasTec, Inc. (NYSE: MTZ), for a fixed price of $296 million which includes an approximately $100 million biomass power plant as part of the facility.

Here we see growth in the alternative energy sector, but is it sustainable without federal subsidies? The only way these sorts of alternative fuels are sustainable now is with higher energy costs. We could see continued subsidies for alternative fuels and higher oil prices. It will be interesting to see if this operation fairs better than the flood of struggling companies in the alternatives fuels industry: QTWW, PEIX.

Always consult a registered investment adviser prior to making investments.  Penny Markets contributors are not registered investment advisers.  Pennystock investments can result in entire loss of investment.

Sunday, October 03, 2010

WLOC, Williow Creek Moves to OTCBB

It does happen, but it does not happen often.  WLOC is graduating in a sense to the OTCBB from the pinksheets.  Listing on the OTCBB will require WLOC to become fully reporting, it does not guarantee the company will be a great success.

"The move back to the OTCBB has been the central focus for our management team. With this hurdle cleared, we will now be able to begin executing our corporate objectives of acquiring and developing mineral properties,"

Pennymarkets and its contributors are not registered financial advisers.  Always contact a registered investment adviser prior to making any investment.

Penny stocks are risky and can result in entire loss of investment.

Saturday, October 02, 2010

ACTC, Advanced Cell Technology Updates on Myoblast

September 29th, Advanced Cell Technology releases update on Phase I of its human clinical trials. ACTC reported that they are in the process of reviewing the results of four independent studies.

"We believe our phase II study would represent one of the most advanced stem cell studies conducted to date," said William M. Caldwell IV, ACT's Chairman and CEO. "In addition to evaluating our clinical options, the Company is also considering the most effective way to finance the cost of the study, which could include grants, partnerships or capital provided by foundations. We are also in negotiations with several countries in Europe to conduct a similar trial. The market potential in the EU is even greater than in the U.S. by up to 50% in patient population size by some estimates."

ACTC has been cleared by the FDA to proceed to phase II trial expected to begin in the second half of 2011.

PennyMarkets contributors are not registered investment advisers.  Always consult a registered investment advisor prior to making any investment.  Investments in pennystocks can result in entire loss of investment.

DIGA,Digital Angel Looks to OTCBB to Change Luck

Digital Angel started out on the OTCBB several years ago, and now they are headed back.  The cost of remaining on the NASDAQ can be cost prohibitive. In recent news the company recently rejected an offer from PositiveID (NASD:PSID) to acquire the company; PositiveID promptly withdrew its offer.
Digital Angel's gross and net income have dipped dramatically over the last three years. It is not clear if the recent decline is intentional, or if demand for the company's product has declined.
On September 29th, the company suggested increased demand for their Destron Fearing electronic identification products in Canada as a result of recent animal health and traceability incentive programs and regulations.

"Federal regulation requires that all Canadian cattle be tagged with an approved Radio Frequency Identification (RFID) tag prior to moving from their current location or leaving their farm of origin. The Canadian Food Inspection Agency (CFIA) is enforcing the national identification and movement reporting requirements for cattle under the authority of the Health of Animals Regulations."

The company has struggled, however they have managed to generate significant revenues.  As an OTCBB company they are attractive because they have  revenue. It will be interesting to see if Digital Angel finds its way to profitability,or if the are acquired!

PennyMarkets contributors are not registered investment advisers.  Always consult a registered investment adviser prior to making any investment.  Pennystock investments can result in entire loss of investment.

Thursday, September 30, 2010

YRCW YRC Worldwide Hits The Skids, Bankruptcy Next?

Today YRC Worldwide hit the skids as share volume spiked and price dropped. I have noticed YRCW over the last few months as the company warned about its mounting debts. It looks like YRCW is about to go the way of Blockbuster, bankruptcy! In many cases shareholders of bankrupt companies get nothing, as seen in many recent mega bankruptcies, like GM General Motors. What's amazing about YRCW at this stage is that there are still analysts willing to offer share price predictions for the common stock.  Listed on Yahoo Finance, the analyst estimate for the share price of YRCW is less than inspiring at just 20 cents.

We are not registered  investment advisers, always consult one prior to making an investment.

Are you tired of the same old promises of investor relations firms? They promise the world and deliver almost nothing.  The new approach to investor relations helps companies develop their products, identify new opportunities, and capitalize on them. If you would like to discuss how we can help your company please visit the about us section.

Take caution when considering a penny stock as an investment! Make sure to contact a registered investment adviser!

Tuesday, September 28, 2010

Pacific Ethanol Signs Over 20% of Facilities for $53 Million

Is Pacific Ethanol foolish for taking on new debt or are they preparing for the loss of six billion in subsidies set to expire in December?  The blenders credit, and another which limits competition from imports. A similar scenario played out last year when a biodiesel subsidies were allowed to expire and were not renewed.

"Pacific Ethanol, Inc. (PEI) (Nasdaq:PEIX), the leading West Coast marketer and producer of low-carbon renewable fuels, announced today several transactions intended to further improve the company's balance sheet and position the company for continued growth in the ethanol industry. On September 27, 2010, PEI entered into agreements to issue senior convertible notes (Notes) in the aggregate principal amount of $35.0 million to institutional investors, which agreements are expected to close on or prior to October 11, 2010. In addition, on September 27, 2010, PEI signed an agreement to sell its minority ownership interest in Front Range Energy, LLC for $18.5 million in cash that is expected to close coincident with the closing of the issuance of the Notes. Total gross proceeds from these two transactions are expected to be $53.5 million. On September 28, 2010, PEI entered into agreements to purchase for $23.3 million a 20% ownership interest in New PE Holdco LLC (New PEH), which is the owner of PEI's previously-owned four ethanol production facilities. As a result, PEI will hold the largest equity ownership position in New PEH. Further, PEI intends to retire $17.0 million in corporate debt, accrued interest and fees owed to Lyles United LLC and Lyles Mechanical Co. (Lyles). The balance of the proceeds is expected to pay transaction fees and to provide approximately $10.0 million of cash reserves to PEI's balance sheet."

Should an IR firm be focused on selling investors, or  product? Our system helps CEOs sell their products and become profitable. Give us a call and we will help determine if your company fits our module.

We are not registered investment advisors. Always contact a registered investment advisor prior to making any investment. Penny stock investments generally result in the entire loss of investment.

Monday, September 20, 2010

ACTC Stock Patent Ignites Interest

On September 14 Advanced Cell Technology released new concerning their Stem Cell-Derived RPE Cells to Treat Eye Disorders. The company reports their patent covers 41 claims covering Stargardt’s disease, retinitis pigmentosa, and macular degeneration.

“We believe that these patents are especially important as they extend the company’s patent coverage of the scalable manufacturing of human RPE cells for therapeutic use, which are core to our technology and product portfolio,” continued Mr. Caldwell. “This IP further expands our patent estate with respect to protecting the use of RPE cells in a wide range of treatments, offering additional validation of the strength and breadth of our patent portfolio. This development also dovetails nicely with the prospect of initiating our human clinical trial for our RPE program. We are optimistic that the methods-of-treatments and the culturing processes covered by these two new patents, along with the Company’s proprietary detection technique for final product release, will establish a formidable barrier to entry for any potential competitors. Once we have begun to treat Stargardt patients, we plan to initiate another clinical trial relating to the use of RPE cells in the treatment of dry Age-Related Macular Degeneration (AMD). At present there is no approved treatment for dry AMD, despite the fact that it represents a $20-30 billion potential market.”

Penny Markets contributers are not registered investment advisors. Prior to any investment please consult an investment advisor. Investment in pennystocks can, and often does result in total loss of investment.

Have you considered the alternative to traditional investor relations? Alternative investor relations has evolved to assist corporations drive sales and increase earnings. Visit the investor relations page to find out more! 

Connect with other ACTC investors on the ACTC investors social network

Tuesday, August 24, 2010

ACTC to Hot to Touch?

Today ACTC announced that their proprietary “embryo-safe” technology will not fall under the recent ban placed on embryonic stem cell research.

Aug. 24, 2010 (Business Wire) -- Advanced Cell Technology, Inc. ("ACT”; OTCBB:ACTC stock news) commented today on yesterday’s federal court ruling, temporarily blocking federal funding for embryonic stem cell research involving the destruction of embryos. The company believes that this will add to the pressure on the NIH to find appropriate sources of human ES cells that can be funded in the context of this preliminary injunction. It is notable, then, that ACT’s proprietary “embryo-safe” Single Blastomere technique for deriving human embryonic stem cells (hESCs), documented in Nature and CELL Stem Cell magazines and elsewhere, does not require destruction of the embryo and as a consequence may not be directly affected by this ruling. ACT does not rely on government funding for any of its research or product development. Accordingly, there is no current impact on the company’s business.

We are not investment advisers, contact one before making any investment decision! Investing in penny stocks can result in total loss of investment.

Tuesday, August 10, 2010

ABK Talks Bankruptcy and Stock Falls

A few months ago I hit a grand slam with my purchase of ABK.  At the time the company reported a sudden turn to profit.  The previous profit Ambac reported was a blip on the radar due to some tax benefits.  The company is once again in financial turmoil and is considering bankruptcy.  A bankruptcy for shareholders of ABK will certainly result in the delisting of ABK shares to the pink sheets or newly formed OTCmarkets. In most cases shareholders are the last to be made whole in bankruptcy and generally receive nothing.  At this time ABK is extremely risky! I'm afraid those who made the last ABK momo play will take it in the shorts if they stick around!

Have you noticed the new trend? Investor relations professionals are finding it more difficult to take restricted and common stock and register it for sale as a corporate entity. The old way of investor relations is on the way out, it's either cash or nothing.
You have heard the pitch before.  Investor relations professionals promise the world, and deliver much less. Find out about the sales approach to investor relations.

PennyMarkets and its contributes are not registered investment advisers, and make no claim to be!  Always consult a registered investment professional prior to making any investment. Investors can, and often do lose all of their investment!

Monday, August 09, 2010

FNM and FRE Demoted to OTCBB

After months of trading on the NYSE has penny stocks, FNM and FRE begin trading on the OTCBB.  In addition to their demotion to the OTCBB, Freddie Mac is seeking an additional 1.8 billion in bailout funds whil Fannie Mae issued a 1.2 billion net loss.  With losses mounting the American tax payer remains on the hook for the losses.

FNM now trades on the OTCBB as FNMA, and FRE now trades as FMCC.

Saturday, July 17, 2010 Replacing Pink Sheets, and OTCBB?

There seems to be a trend developing in the penny stocks market. Pink Sheets dot com is no longer a live web site, rather, it has been replaced with  The new OTCmarkets portal offers insightful information, and has broken the status of pinksheet stocks down in to several easily identifiable categories.  The category designations are supposed to help investors determine what level of risk they are encountering in the market.

Monday, June 21, 2010

CMZ Compton Petroleum Improving Debt Position

I was introduced to Compton by a class mate, an accounting major.  He liked the company and thought they were going to do well, however, the stock has not done well. Perhaps now is a better entry point. We are not certain an improved debt position makes the company any more attractive.

About Compton Petroleum Corporation
Compton Petroleum Corporation is a public company actively engaged in the exploration, development and production of natural gas, natural gas liquids, and crude oil in western Canada. Our strategy is focused on creating value for shareholders by providing appropriate investment returns through the effective development and optimization of assets. The Corporation's operations are located in the Deep Basin fairway of the Western Canada Sedimentary Basin. In this large geographical region, we pursue three deep basin natural gas plays: the Gething/Rock Creek sands at Niton and Gilby in central Alberta, the Basal Quartz sands at High River in southern Alberta, and the shallower Southern Plains sand play in southern Alberta. In addition, we have an exploratory play at Callum/Cowley in the Foothills area of southern Alberta. Being in the Deep Basin, all areas have multi-zone potential, providing future development and exploration opportunity. Natural gas represents approximately 84% of reserves and production. Compton's shares are listed on the Toronto Stock Exchange under the symbol CMT and on the New York Stock Exchange under the symbol CMZ.

Always consult a registered investment adviser before making any investment decision.  We are not investment advisers!  We have not been compensated for the display of this information. Occasionally thinly traded corporations  compensate investor relations firms with stock, or cash to display information. In the past has been compensated, however, is not now being compensated.  Please review our disclaimer for our past participation.

Thursday, April 29, 2010

OTCBB Penny Stocks Morning News April 29, 2010

Revonergy Inc. Announces Private Placement Financing
Revonergy Inc. ("Revonergy" or the "Company"), (symbol OTCBB-RNRG penny stocks) announces the Company has successfully completed

VSI Selected to Secure 700 Sites
Viscount Systems (OTC:VSYS) announced today that the company's MESH technology platform has been

Alamo Energy Corp. Provides Operational Update for April
Alamo Energy Corp. (OTCBB:ALME - News), an independent company focused on the exploration, development and

New Energy Completes Commercial-Scale Prototype Able to Generate Electricity
New Energy Technologies, Inc. (OTC:NENE) , developer of MotionPower(TM) technologies for generating

OTC Global Holdings Announces Formation of Edge Environmental
Global Holdings, a leading independent inter dealer broker in the over-the-counter space, announced today the formation of

SISM Research Initiates Independent Research Coverage On Grid Petroleum
Ernest C. Schlotter, a senior analyst with SISM Research and a four star

Consorteum Holdings Inc. Organizes Initiatives for Streamlined Efficiency
Consorteum Holdings, Inc. (OTCBB: CSRH) today announces its intent to divide the company into the operational divisions it has

Bioject Announces Results of Intradermal Dose Sparing Influenza Study
Bioject Medical Technologies Inc. (OTC:BJCT) , a leading developer of needle-free injection therapy systems

Allied Security Innovations Seeing Rebound in 2010
Allied Security Innovations (OTCBB: ADSV) owner of CGM-AST, a leading manufacturer of tamper-evident

I happen to like a small company SYNM. They are not the normal penny stock you expect. SYNM is earning money and profitable. Syntroleum is in a relationship with Tyson foods to build a processing plant which will convert Tyson's fat byproducts into fuel! Tyson is serious about the relationship and has purchased several rendering plants to keep the joint venture processing plant at full capacity. Take a serious look at SYNM!

Jason Buchen is not a registered investment adviser. This information is not provided as an attempt to advise about investments. Always consult an investment adviser prior to making an investment decision. Investing in penny stocks can and usually does result in a total loss of investment. Jason Buchen has not knowingly been compensated for any of the information provided in this blog post. Any compensation knowingly received by Jason Buchen for comments on this blog can be found in the disclaimer. Additionally, Jason Buchen does not own any of the of the companies mentioned in this blog post.

Friday, April 23, 2010

Is Proteonomix For Real?

PROT has recently announced it's intention to list on the OTCBB. I have always taken a more serious look at companies graduating from the pink sheets (now otcmarkets). Proteonomix is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. Proteonomix has facilities at a number of academic institutions. Its subsidiary, Proteoderm has developed a line of anti-aging cosmetics. The company has experienced some price appreciation since December of 2009. Additionally, there have been two insider purchases at $1.5

This information was collected from otcMarkets.

This is not a solicitation to buy or sell a security. Additionally, we have not been compensated for the production of this material. Please consult a registered investment advisor prior to making any investment decision.

Wednesday, March 17, 2010

Should Best Buy Buy Blockbuster?

Would it be a match made in heaven? Would Best Buy benefit from all the smaller locations Blockbuster has accumulated over the years? Additionally, would it be a good move for Best Buy to acquire Blockbusters kiosk and online video distribution? Although there is a weak connection here, I believe it is one worth exploring.

Any thoughts?


Monday, March 15, 2010

ADXS Develops New Sorage For Listeria

NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)-Advaxis Inc., (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company has developing a long-term, room temperature, storage-stable form of its vaccines. This would replace the current requirement to keep the product frozen at -70o C before use.

Wednesday, March 03, 2010

Global Med Technologies

I am a shareholder of Global Med Technologies. I have a modest position of just ten shares. Recently I received a document requiring my vote on weather to allow a firm to purchase Global Med. The proposed purchase price is $1.22 per share, well below what I believe the firm is worth. However, $1.22 is significantly higher than the current book value of the firm, just eight cents. Currently the firm has more debt than cash, and their profit margin is a meager 3.24%. Although I do not want this acquisition to occur, I believe it is the best option for the firm and its shareholders.

I would like to thank Michael Ruxin for his years of dedicated service as the CEO of Global Med Technologis. I look forward to investing in his next venture.

Sunday, January 31, 2010

Why Do Investors Buy Penny Stocks?

Investors buy penny stocks for a number of reasons, some are financial gain, the hunt, and  inexperience!
Penny stocks can be found on all exhanges. Those exchanges include the Pink Sheets, OTCBB, NASDAQ, NYSE, and AMEX. The riskiest of these exchanges are the Pink Sheets, and OTCBB. Many of the companies listed on these exchanges are under funded and require additional capital raises. This activity generally poses additional risk for investors. Companies listing on the larger exchanges, AMEX, NASDAQ, and NYSE, tend to be more stable. However, stocks which have fallen below their required listing price can become very unstable because their listing status on these exchanges becomes uncertain. This uncertainty can cause stock prices to fluctuate greatly.
Investors who purchase these stocks on the pink sheets should have a great understanding of the market and its requirements for those issues to continue trading on the pinks. For instance, pink sheet stocks can lose their right to be traded, or fall to lower levels of quotation if they fail to meat minimum requirements.
There are five levels on the pink sheets. Those levels are OTCQX, Current Information, Limited Information, No Information, and Caveat Emptor. With each level the underlying securities become less liquid, and are subsequently harder to sell. These statuses can and do change often with little or no notice, and that's why trading pink sheets should only be done with a great deal of understanding.
Penny stocks traded on the OTCBB market are also risky. Many times stocks which were listing on higher exchanges choose to be listed on the OTCBB because it is easier to meet their listing requirements. Additionally, liquidity is a concern for penny stocks trading on the OTCBB exchange. Companies listed on the OTCBB exchange also rely on funding practices which can result in unfavorable terms for common shareholders.
Companies listed on the major exchanges, AMEX, NYE, and NASDAQ, tend to be more stable than those penny stocks listed on the other two exchanges. However, all penny stocks are risky, and should only be purchased with capital which can ultimately be lost.
Investors tend to believe that purchasing a penny stock creates a larger potential for gain. If the investor takes the time to review financial statements of penny stocks, they will find that the majority of them are already overvalued. However, some penny stocks do represent the potential for great gains, though many do not!
Some investors enjoy sifting through penny stocks seeking the diamond in the rough,the hunt. Their are a few companies which are under valued or represent a great deal of potential. These companies which have great potential require the perfect storm to realize great gains.
Many penny stocks are purchased by investors who are inexperienced traders. These investors are referred to penny stock investments by friends, family, and random sources. The random sources of information can be ads, email, or web pages. These sources are generally compensated to provide the information and they should display the compensation. If you ever find one of these sources of information you should look for the pages disclaimer and read it!
Don't buy a penny stock if you do not have intimate knowledge about the company and its situation.

All in my honest opinion, consult an investment advisor prior to making any investment decision!

Wednesday, January 20, 2010

SIBN Has Solid Trading Day

Shares of SIBN rose 225% on 300,000 shares traded. The company has no revenue, and is losing money. Additionally, the company has 500,000 in debt and 700 in cash.

I found this information in the most recent 10Q for SIBN

previously loaned to KNG, and $1,406 of property and equipment, net.
We had total liabilities of $2,206,752 as of September 30, 2009, which were solely current liabilities and which included $505,211 of accounts payable to related party stockholders in connection with those shareholders paying certain of our expenses from the period between January 1, 2003 to September 30, 2009; $67,316 of accounts payable to Baltic in connection with a $29,000 loan advanced to the Company from Baltic and certain other expenses owed to Baltic; $565,013 of accounts payable to others for advisory and professional services rendered; and $1,069,212 of accrued payroll, which included $607,500 payable to our Chief Executive Officer, David Zaikin, of which $360,000 was accrued in 2007 and 2008, and $112,500 which was owed to Mr. Zaikin for services rendered prior to September 2005, at which time he agreed to stop accruing salary until January 2007, when he provided us notice of his intent to once again begin accruing salary until such time as we have sufficient funds to pay such accrued salary, $218,537 payable to our Chief Financial Officer, Elena Pochapski, and $69,242 of accrued salary payable to our former Chief Executive Officer, Shakeel Adam.

We had negative working capital of $2,205,438 and a total pre-development and development stage accumulated deficit of $15,341,744 as of September 30, 2009.

Because our cumulative losses associated with the operations of ZNG exceeded our investment as of the date of the Joint Venture, ZNG, Ltd. is carried on our balance sheet at $-0- as of September 30, 2009. Our investment in ZNG, Ltd. will exceed $-0- at such time as ZNG, Ltd. has cumulative earnings sufficient to repay all loans to Baltic as provided in the Joint Venture, if ever.

As of September 30, 2009, the Company owns a 44% interest in KNG. The Company’s investment in KNG is recorded on the equity method of accounting effective October 1, 2008. After careful consideration of the current financial position of KNG, the Company applied an impairment charge to the value of the investment in KNG which resulted in carrying it at zero value.
We had $14,592 of net cash flows from operating activities for the nine months ended September 30, 2009, which was attributable to adjustments to reconcile $485,355 of net loss, offset by $461,535 of accounts payable and accrued expenses, $458 of depreciation and amortization, $37,989 of common stock and warrants issued for services and increased by $35 of prepaid expenses and other assets.

In connection with the Joint Venture (described under "Joint Venture," above), the Company historically received management fees, which varied from $25,000 to $85,000 per month. Due to the “transition period” of the Joint Venture’s exploration activities, no management fees were paid during the year ended December 31, 2008 or the nine months ended September 30, 2009, and the Company does not anticipate receiving any such fees moving forward. If the Company does not receive any management fees moving forward, the Company anticipates that its stockholders and management will continue to provide financing for the Company, of which there can be no assurance.

Sunday, January 17, 2010

NEOP Neoprobe

Neoprobe has had a great run over the last few months.

The company has some cash however, they have more debt than cash. Additionally, Neoprobe has a negative book value, I would be very cautious with NEOP at this point. I am not a shareholder in Neoprobe, and likely will not become one any time soon.

Total Cash (mrq):6.03M
Total Cash Per Share (mrq):0.075
Total Debt (mrq):10.95M
Total Debt/Equity (mrq):N/A
Current Ratio (mrq):3.55
Book Value Per Share (mrq):-0.133